DALLAS, April 21, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Array BioPharma Inc. (Nasdaq:ARRY). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/ads/ARRY
Array BioPharma Inc. (ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. In addition, pharmaceutical and biotechnology companies collaborate with the Company to discover and develop drug candidates across a range of therapeutic areas. The Company has seven wholly owned programs in its development pipeline: ARRY-403, a glucokinase activator for type 2 diabetes; ARRY-162, a MEK inhibitor for rheumatoid arthritis and cancer; ARRY-380, an ErbB-2 inhibitor for breast cancer; ARRY-520, a KSP inhibitor for acute myeloid leukemia and multiple myeloma; ARRY-614, a p38/Tie 2 dual inhibitor for myelodysplastic syndrome; ARRY-543, an ErbB family (ErbB-2 / EGFR) inhibitor for solid tumors, and ARRY-797, a p38 inhibitor for subacute pain and cancer supportive care indications.
Message Board Search for ARRY: http://www.boardcentral.com/boards/ARRY
In the report, the analyst notes:
"ARRY shares were boosted after the Company's recent announcement that it licensed a group of experimental cancer treatments to drugmaker Novartis, an agreement that ARRY CEO Robert Conways calls a major advance in the Company's 'strategic objective to become a fully integrated, commercial-stage biopharmaceutical company.'
"Under the terms of the deal, ARRY will initially receive $45 million comprising an upfront and milestone payment and is eligible to receive an additional $422 million if certain clinical, regulatory and commercial milestones are achieved."
To read the entire report visit: www.microstockprofit.com/ads/ARRY
See what investors are saying about ARRY at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com.
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.